Syner-G BioPharma Group

Name

Syner-G BioPharma Group

Legal name

Syner-G BioPharma Group

Website

https://synergbiopharma.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Product category

Biopharma Development Consulting

NAICS

Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (54169), Other Management Consulting Services (541618)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Management Consulting Services (8742)

akta.pro primary industry

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

akta.pro secondary industries

GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), CMC, Process Development & Tech Transfer Staffing FSP (HLAGAOAK), GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL)

Keywords

• CMC regulatory services
• Biopharma consulting
• Pharmaceutical development
• GMP operations support
• Drug development advisory

Headquarters

HQ city

Southborough

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Consulting and Development Services: Syner-G generates revenue through providing strategic consulting, scientific, regulatory, quality, and technical operations services to biopharma companies. Services include regulatory strategy, CMC development, quality compliance, and program management support delivered through embedded team engagement.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Syner-G BioPharma Group is a strategic development and delivery partner to biopharma innovators, providing integrated scientific, regulatory, quality, and technical operations expertise across the drug development lifecycle. The firm delivers CMC strategy and development, regulatory strategy and medical writing, quality and compliance, GMP operations and engineering, program and portfolio management, and clinical services, embedded within client teams from discovery through commercialization.

Product overview

Syner-G BioPharma Group is a strategic development and delivery partner for biopharma innovators, offering an integrated suite of consulting and support services across the entire drug development lifecycle. The company's offerings are organized into three core service pillars: Scientific, Regulatory & Quality Solutions; Strategy & Transformation Consulting; and Technical Operations & Delivery Infrastructure. These services are delivered across multiple company stages (Emerging & Early-Stage Biotech, Mid-Sized to Large Enterprise Biopharma, Private Equity & Investors), development stages (Discovery, Preclinical, Clinical, Commercialization), and product modalities (Biologics, Small Molecule, Cell & Gene Therapy, Diagnostic & Medical Device). Key specific service offerings include CMC Strategy & Development, Regulatory Strategy, Medical Writing, Quality & Compliance, GMP Operations & Engineering, Program & Portfolio Management, and Business Excellence. The company does not offer a software product but rather provides expert consulting and operational support services.

Differentiator

Problem solved

Functional benefit

Products and services

• Scientific, Regulatory & Quality Solutions Integrated scientific, regulatory, and quality expertise guiding therapies through drug development from preclinical to commercialization, minimizing risk and streamlining progress. Offered to biopharma companies of all stages and sizes.
• Strategy & Transformation Consulting Top-tier consulting experience and deep life sciences expertise driving strategic initiatives across M&A integration, AI and digital transformation, and organizational design for biopharma clients.
• Technical Operations & Delivery Infrastructure Technical expertise, operational leadership, and hands-on support to turn strategy into scalable, compliant execution; embedded alongside client teams to lead technical operations and infrastructure.
• CMC Strategy & Development Chemistry, Manufacturing, and Controls (CMC) strategy and development support for drug development programs.
• Quality & Compliance Quality assurance and regulatory compliance services for GxP environments.
• Regulatory Strategy Regulatory strategy development and consulting services for FDA and global health authority interactions.
• Medical Writing Regulatory medical writing services including IND submissions, DSURs, clinical study reports, and marketing applications.
• GMP Operations & Engineering Good Manufacturing Practice (GMP) operations and engineering support services.
• Program & Portfolio Management Program and portfolio management services for drug development operations.
• Clinical Services

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Partnerships

One partnership is on record.

• BetterLife Pharma Inc.key client engagementStrategic or Co-development Partner · 25 June 2026BetterLife Pharma engaged Syner-G to oversee GMP manufacturing of BETR-001, its non-hallucinogenic LSD-derivative candidate being developed for chronic cluster headache and chronic migraine. Syner-G provides CMC and regulatory expertise to support the company's path to first-in-human clinical studies, with IND filing and Phase 1 trials projected for Q1 2027.

Scale indicators3 records

Recent moves6 records

Direct peers

• ProPharma Group: ProPharma Group is a pharma consulting and compliance services firm offering regulatory affairs, CMC, quality, and clinical services. It is highly comparable as a direct competitor for CMC, regulatory, and quality consulting mandates with embedded delivery models.
• RMC Pharmaceutical Solutions: RMC Pharmaceutical Solutions (acquired by Syner-G in 2023) was an independent CMC consulting firm — its prior independent peer set maps directly to Syner-G's small-molecule CMC and regulatory service line.
• Halloran Consulting Group: Halloran is a life-sciences consulting firm focused on CMC, quality, regulatory, and program management for emerging and mid-size biotech. It competes head-to-head with Syner-G's fractional CMC and regulatory advisory offering.
• Pace Life Sciences: Pace Life Sciences provides CMC, analytical development, and regulatory consulting services to pharma and biotech. It is a direct peer in CMC strategy, small-molecule development, and regulatory support.

Broad incumbents

• Pharmaron: Pharmaron is a global CRO/CDMO offering integrated drug discovery, CMC, manufacturing, and clinical services. It is a broad incumbent peer offering overlapping CMC and regulatory services across the full lifecycle.
• Catalent: Catalent is a global CDMO providing development, manufacturing, and regulatory services across modalities including biologics and cell/gene therapy. It competes with Syner-G's biomanufacturing and CMC service lines as a much larger incumbent.
• QPS Holdings: QPS is a global CRO offering preclinical, CMC, clinical, and bioanalytical services. It overlaps with Syner-G's CMC and clinical-stage service offerings across small molecules and biologics.
• Charles River Laboratories: Charles River is a major CRO/CDMO with broad CMC, biologics, and regulatory consulting capabilities. It overlaps with Syner-G's biologics and small-molecule development offerings as a large, diversified incumbent.

Emerging players

• Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-size CRO with scientific and regulatory expertise supporting biotech programs. It is comparable as an emerging player offering overlapping CMC-adjacent and regulatory services.
• CROMSOURCE: CROMSOURCE is a mid-size CRO providing clinical and related development services with growing CMC exposure. It is comparable as an emerging global player in the same biopharma services space as Syner-G.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles24 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Syner-G BioPharma Group